Novartis pelacarsen lowered Lp(a) levels in 8,323 patients—but didn't reduce cardiovascular events

On September 4, 2026, Novartis and its partner Ionis Pharmaceuticals announced topline results from the Lp(a)HORIZON Phase 3 cardiovascular outcomes trial (NCT04023552).

Episode metadata supplied by the publisher feed · Published Sep 7, 2026

Embed this episode

Attribution link and audio player

Ready to play

Novartis pelacarsen lowered Lp(a) levels in 8,323 patients—but didn't reduce cardiovascular events

0:00 9:09

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Onpode?

This episode is 9 minutes long.

When was this Onpode episode published?

This episode was published on September 7, 2026.

Can I download this Onpode episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!